Candesartan's Effects on Alzheimer's Disease And Related Biomarkers

Exclusion Criteria

• •Intolerance to ARBs
• •Current use of ARBs, angiotensin-converting enzyme inhibitors (ACEIs) (use of antihypertensive medications other than ACEI or ARBs for other indications is allowed)
• •Current diagnosis of hypertension or current use of antihypertensive medication that is prescribed specifically for hypertensive therapy
• •SBP less than 110 or DBP less than 40 mm Hg
• •Renal disease (Creatinine \>2.0 mg/dl), hyperkalemia (K\>5.5 meq/dl), platelets\<50,000/μl, or international normalized ratio (INR)\>1.9
• •Active medical or psychiatric diseases that in the judgment of the investigator would affect the safety of the subject or scientific integrity of the study
• •Uncontrolled congestive heart failure reflected by poor exercise tolerance and shortness of breath
• •History of stroke in the past 3 years
• •Inability to have MRI (eg metal implants or cardiac pacemaker) with an exception for those who cannot have an MRI, if all other parts of the study are obtained successfully they may still be enrolled in the study, or cognitive assessment or inability to assess amyloid positivity (no lumbar puncture and no amyloid scan)
• •History of increased intracranial pressure (ICP) or bleeding diathesis (from disease states or from use of anticoagulants such as warfarin, heparin and related products, rivaroxaban or Xarelto, apixaban or Eliquis, edoxaban or Savaysa, dabigatran or Pradaxa)
• •Women of childbearing potential (non-menopausal)
• •In those who are unable to demonstrate that they understood the details of the study (ie lack of decisional-capacity to consent), a study partner/surrogate who can sign on their behalf will be required, otherwise they will be excluded
• •Current use of Lithium, as candesartan may increase lithium concentration to toxic levels